← All trials
NCT04315792
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- May 31, 2021
- First posted
- Mar 20, 2020
- Last posted
- Mar 20, 2020
- Enrollment
- 124
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jina Pharmaceuticals, Inc.Lead sponsor
- Lambda Therapeutic Research LtdCollaborator
- Novum Pharmaceutical Research ServicesCollaborator
- Intas Pharmaceuticals LimitedCollaborator
- Innovative Clinical Research, Inc.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.